Financière de Tubize S.A.

Board/Management Information • Aug 22, 2025

Nomination of Iris Löw-Friedrich (64) as director(1)

Education

1985	Medical School, Goethe University Frankfurt, MD
1985	Max Planck Institute for Physics, Germany, PhD, Biophysics

Professional experience

UCB
Executive Vice President, Head of Development & Chief medical Officer, Belgium
Global Head of R&D, Schwarz Pharma, Germany
BASF, Vice President & head of Global Projects, Germany
Sanofi
Vice President & Head of Global Clinical Management, NJ, USA
Vice President & Head of Global Therapeutic Area Rhumatology, Immunology, Bone Disease, HMR
Global Drug Development Center, NJ, USA
Clinical Research Physician, Study Director, Germany
Johann Wolfgang Goethe-Universität Frankfurt am Main, Germany
Associate Professor, Internal Medicine
Staff Physician, Internal Medicine, Immunology, Nephrology & Transplantation Medicine

Current Directors mandates

• Zogenix (since 2022)
• Evotec (Chairwoman, since 2021)
• TransCelerate BioPharma (since 2017)
• Fresenius (since 2016)

Recommendation of the board of directors

The board of directors formulates a unanimous favourable advice on the candidature of Mrs. Iris Löw-Friedrich as director of the Company. Mrs. Iris Löw-Friedrich has the qualifications, skills, knowledge, experience and integrity to make a valuable contribution to the functioning of the board of directors. She committed to make sufficient time available for exercising her mandate.

(1) For a period of four years ending on the ordinary general meeting of 2029.

1